The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

MLA

Warrilow, Andrew G. S., et al. “The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 8, July 2016, pp. 4530–38. EBSCOhost, https://doi.org/10.1128/AAC.00349-16.

APA

Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2016). The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme. Antimicrobial Agents and Chemotherapy, 60(8), 4530–4538. https://doi.org/10.1128/AAC.00349-16

Chicago

Warrilow, Andrew G S, Josie E Parker, Claire L Price, W David Nes, Edward P Garvey, William J Hoekstra, Robert J Schotzinger, Diane E Kelly, and Steven L Kelly. 2016. “The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.” Antimicrobial Agents and Chemotherapy 60 (8): 4530–38. doi:10.1128/AAC.00349-16.